Palvella Therapeutics, Inc. (PVLA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$157.24+1.14%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PVLA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -63.2% |
| Our one-year growth estimate | diamond | -24.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 38.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PVLA — earnings miss
Dated 2026-08-04
Results of Operations and Financial Condition. On August 4, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section…
Why it matters: The NDA submission is key for regulatory approval. It shows the company is on track.
Supportive ifManagement confirms the NDA submission is on track for the second half of 2026.
Worry ifManagement delays the NDA submission. They do not give updates.
Why it matters: Updates on launch plans will show if the product is ready for market entry if approved.
Supportive ifManagement says they are making progress on pre-launch activities for QTORIN rapamycin. This is happening in the first half of 2027.
Worry ifNo updates or signs of progress in launch preparations by early 2027.
Why it matters: Good results could show that QTORIN rapamycin works for angiokeratomas. This could grow its market.
Watch forTopline results from the Phase 2 LOTU trial are reported in the second half of 2027.
Also watch forTopline results from the LOTU trial are disappointing or delayed beyond the second half of 2027.
Why it matters: If the healthcare sector shows renewed growth, it may benefit Palvella. This could improve investor outlook.
Supportive ifHealthcare sector revenue growth is speeding up. It is getting close to 10% or more.
Worry ifHealthcare sector revenue growth remains below 5%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$226 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $717 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,111 loss on $10,000 · 31.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this trial is crucial for expanding the QTORIN rapamycin pipeline. It could lead to new treatment options for patients.
Supportive ifPalvella will start the Phase 3 trial for QTORIN rapamycin in Q4 2026.
Worry ifPalvella delays the initiation of the Phase 3 trial beyond Q4 2026.
Why it matters: These results will show how well the company is doing financially and how it runs.
Watch forFinancial results show smaller losses or more money coming in than before.
Also watch forFinancial results show bigger losses or no increase in money coming in.
Why it matters: Updates on the FDA approval timeline will clarify the path to market for their drug. This is crucial for investors.
Supportive ifManagement says they are on track for FDA approval by early 2027.
Worry ifManagement says FDA approval will be delayed past early 2027.
Why it matters: Completing the NDA submission is key for FDA approval. It may lead to the first therapy for microcystic lymphatic malformations.
Supportive ifNDA submission for QTORIN rapamycin is completed by the end of 2026.
Worry ifThe NDA submission is delayed beyond 2026.
Why it matters: Starting this trial is key for QTORIN rapamycin's use. It shows a commitment to clinical development.
Supportive ifThe Phase 3 trial for cutaneous venous malformations begins as planned in Q4 2026.
Worry ifThe Phase 3 trial initiation is postponed beyond Q4 2026.